Barclays
GCTK icon

Barclays’s GlucoTrack GCTK Stock Holding History

Barclays’s Portfolio GCTK Stock Details GCTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-751
Closed -$4.51K – 5573
2025
Q2 		$4.51K Buy
+751
New +$6.6K ﹤0.01% 4985

Other funds holding GCTK

AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Barclays's GCTK Position: Q3 2025 in Review

Barclays sold out of GlucoTrack (GCTK) in Q3 2025, closing a stake of 751 shares — an estimated $4.51K sold.

Barclays first reported a position in GCTK in Q2 2025 and held it in 1 quarter. The position peaked at $4.51K in Q2 2025. 8 funds tracked by Wall St. Rank hold GCTK as of Q3 2025.

  • Barclays reported no remaining GlucoTrack position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 751 GlucoTrack shares in Q3 2025, an estimated $4.51K.
  • Barclays first reported a position in GlucoTrack in Q2 2025 and held it in 1 quarter.
  • Barclays's GlucoTrack position peaked at $4.51K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held GlucoTrack as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.